Holen Sie sich die Stockscreener-App
14.56
0.75%
-0.11
Schlusskurs vom Vortag:
$14.67
Offen:
$14.83
24-Stunden-Volumen:
2.82M
Relative Volume:
0.92
Marktkapitalisierung:
$3.10B
Einnahmen:
$61.10M
Nettoeinkommen (Verlust:
$-138.36M
KGV:
-10.79
EPS:
-1.35
Netto-Cashflow:
$-90.59M
1W Leistung:
+15.74%
1M Leistung:
+26.72%
6M Leistung:
+62.68%
1J Leistung:
+63.78%
1-Tages-Spanne:
$14.35
$15.38
1-Wochen-Bereich:
$14.35
$16.44
52-Wochen-Spanne:
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Vergleichen Sie OCUL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
14.56 | 3.13B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-11 | Eingeleitet | Needham | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission - Insider Monkey
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application - Insider Monkey
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Is Ocular Therapeutix Inc a good long term investmentAnalyst Downgrades & Big Gains Low Investment - earlytimes.in
(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025 - ts2.tech
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Chardan Capital Maintains Buy Rating on OCUL with $21 Price Targ - GuruFocus
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD - Eyes On Eyecare
Ocular Therapeutix: Not So Fast On The Single-Trial Bet (Rating Downgrade) (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix stock price target raised to $30 by RBC on wAMD trial outlook - Investing.com Canada
Ocular Therapeutix stock hits 52-week high at 14.79 USD By Investing.com - Investing.com Canada
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
OCUL Stock Surge: Analysts Weigh In - StocksToTrade
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission By Investing.com - Investing.com Australia
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission - Investing.com
Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug - Sahm
Why Is Ocular Therapeutix Stock Skyrocketing Monday?Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
Paramount Skydance, Wave Life Sciences, Ocular… - inkl
Ocular Therapeutix (NASDAQ:OCUL) Receives Buy Rating from Needham & Company LLC - MarketBeat
OCUL: Needham Reiterates Buy Rating with $20 Price Target | OCUL Stock News - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year HighHere's Why - MarketBeat
Ocular Therapeutix stock price target raised to $28 from $19 at Raymond James - Investing.com Canada
Ocular Therapeutix stock hits 52-week high at 14.79 USD - Investing.com
Ocular Therapeutix Inc.’s Breakthrough: Will It Spark a Surge? - timothysykes.com
OCUL's Target Price Raised to $21 by HC Wainwright & Co. | OCUL Stock News - GuruFocus
Ocular Therapeutix (OCUL) Plans NDA Submission for Wet AMD Treat - GuruFocus
H.C. Wainwright raises Ocular Therapeutix stock price target to $21 on FDA pathway - Investing.com UK
Ocular Therapeutix says SOL-1 topline data expected in first quarter 2026 - marketscreener.com
Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug - TradingView
Ocular Therapeutix Plans NDA Submission for AXPAXLI in Wet AMD Following Positive SOL-1 Year One Data - Quiver Quantitative
Ocular Therapeutix, Inc. Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD - marketscreener.com
Ocular Therapeutix, Inc. $OCUL Position Boosted by Pale Fire Capital SE - MarketBeat
Ocular Therapeutix prepares NDA submission for wet AMD drug - MSN
AXPAXLI NDA Acceleration Might Change The Case For Investing In Ocular Therapeutix (OCUL) - Sahm
Ocular Therapeutix reports inducement grant under NASDAQ listing rule - MSN
Ocular Therapeutix (OCUL): Is the Recent Share Price Momentum Backed by Its Valuation? - Sahm
Ocular Therapeutix (OCUL) Valuation After Accelerated AXPAXLI NDA Plan in Wet AMD - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges - ts2.tech
Ocular Therapeutix plans new drug application for AXPAXLI based on Phase 3 data - Investing.com Nigeria
Ocular Therapeutix Plans NDA Submission for Wet AMD Treatment - TradingView
Ocular Therapeutix (NASDAQ:OCUL) Trading Up 12.3%What's Next? - MarketBeat
With Ocular Therapeutix Stock Surging, Have You Considered The Downside? - Trefis
Ocular Therapeutix reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Saturn V Capital Management LP Purchases 130,385 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
What sentiment indicators say about Ocular Therapeutix Inc. stockWeekly Trade Recap & High Return Trade Opportunity Guides - Newser
How Ocular Therapeutix Inc. stock reacts to inflationary pressuresDollar Strength & Reliable Breakout Forecasts - Newser
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):